| Issue |
E3S Web of Conf.
Volume 553, 2024
2024 International Conference on Ecological Protection and Environmental Chemistry (EPEC 2024)
|
|
|---|---|---|
| Article Number | 05024 | |
| Number of page(s) | 5 | |
| Section | Medical Treatments and Therapies | |
| DOI | https://doi.org/10.1051/e3sconf/202455305024 | |
| Published online | 24 July 2024 | |
The therapeutic effect and mechanisms of ABP501, an adalimumab biosimilar, in rheumatoid arthritis
School of Medical Instruments, Shanghai University of Medicine & Health Sciences, Shanghai, 200237, China
* Corresponding author: 631402070210@mailscqjtu.edu.cn
Adalimumab is one of the most widely used antibodies in the world. With the expiration of its patent rights, a large number of drugs with similar biological functions began to emerge. There are already three ADalimumab generic drugs in Europe and/or the United States: ABP501 (AMJEVITA/Solymbic) produced by Amgen, BI695501 (Cyltezo) produced by Boehringer-Ingelheim, and SB5 (Imraldi) produced by Samsung. All three agents meet the predetermined reciprocity criteria. Adalimumab inhibits the biological activity of TNF- α by inhibiting the binding of TNF- α to P55 and p75. The researchers point out that there are small differences in side effects and clinical reactions between reference drugs and similar drugs. In this study, the biological experimental results of RA were analyzed and evaluated. The launch of biological generics of adalizumab will provide us with an exciting opportunity to provide more choices for our patients in RA and other approved drugs. In order to better ensure its correctness and security, it is also necessary to use actual data.
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.